Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CardiALLO cell therapy - BioCardia

Drug Profile

CardiALLO cell therapy - BioCardia

Alternative Names: Autologous human bone marrow cells - BioCardia; Autologous human mesenchymal cells - BioCardia; BCDA 03; BCDA 04; BCDA-03-CardiALLO cell therapy; CardiALLO; Neurokinin 1 receptor positive mesenchymal stem cell therapy - BioCardia; NK1R+ MSC

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioCardia
  • Class Cell therapies; Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Heart failure
  • Phase II Left ventricular dysfunction; Myocardial infarction
  • Preclinical SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 27 Mar 2024 Efficacy and adverse events data from a phase I/II trial in Heart failure and Left ventricular dysfunction released by BioCardia
  • 08 Sep 2023 BioCardia initiates a phase I/II trial for Heart failure(Intracoronary) in the USA (NCT05925608)
  • 09 Aug 2023 BioCardia plans a phase I/II (BCDA-03) trial for heart failure with reduced ejection fraction (HFrEF) in the third quarter of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top